Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR/c-Met bispecific antibody MCLA-129

A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met bispecific antibody MCLA-129 simultaneously targets and binds to the extracellular domains of both EGFR and c-Met expressed on cancer cells. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways. The binding results in antibody-dependent cellular cytotoxicity (ADCC), thereby inhibiting tumor cell proliferation and survival. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Synonym:bispecific EGFR-c-Met antibody MCLA-129
Code name:MCLA 129
MCLA-129
MCLA129
Search NCI's Drug Dictionary